The scale of veterinary market seedlings will be expanded by 20 billion yuan in 10 years.

Benefiting from the increasing scale of aquaculture and the epidemic prevention policy of "giving priority to prevention and supplemented by culling", the US animal vaccine industry ushered in a period of vigorous development from 2001 to 2009, with the market size doubling from US $600m to US $1.2 billion, with a compound annual growth rate of 9 per cent, much higher than the 5 per cent growth rate of the animal protection industry in the same period. After that, due to the implementation of the defense system of "culling mainly and defense as a supplement", it gradually entered a period of steady development.

China's animal vaccine will usher in a golden period of market-oriented development, and there is a lot of room for growth. Through a comparative study of the animal vaccine market in developed countries and the development process of human vaccine in China, it is found that the animal vaccine market in China can be compared with the great development period of the animal vaccine market in the United States from 2001 to 2009. and the rapid quadrupling of China's human vaccine market from 2005 to 2009. The author judges that China's animal vaccine industry has experienced a period of rapid development of government-procured vaccines in the past 10 years, and will enter a period of great development of the market vaccine in the next 10 years. The market scale is expected to rise from 9 billion yuan at present to more than 30 billion yuan, with huge growth space.

The author believes that the four major factors will drive the development of the animal protection industry, "volume and price rise" to promote the performance of high-quality companies in the industry. The threshold for entering the animal vaccine industry is high, and the scale of the breeding industry is the sustainable driving force for the development of the animal vaccine industry; product innovation and production process upgrading lay the foundation for the great development of high-quality market vaccines; the expectation of the market-oriented recruitment reform of the government's strong immune vaccine and the innovation of the marketing mode of the market vaccine stimulate the market demand for high-quality vaccine. The animal vaccine market is relatively closed, which is beneficial to the development of domestic leading enterprises, and finally forms the situation of permanent strength and oligopoly of the strong. Large varieties of market seedlings "volume and price rise" to promote the growth of industry scale and company performance.

With the rapid development of the industry, the author believes that the market scale of foot-and-mouth disease, highly pathogenic avian influenza, highly pathogenic pig blue ear, classical swine fever and pig ring vaccine can be increased from 2.5 billion yuan to 3 billion yuan, 1.8 billion yuan, 1.2 billion yuan, 700 million yuan, 1.2 billion yuan and 1.4 billion yuan to 10.3 billion yuan, 2.7 billion yuan, 2.7 billion yuan, 1.3 billion yuan and 3.5 billion yuan, respectively.

Specifically, the market vaccine of foot-and-mouth disease has yet to be developed, which is the key area of enterprise competition in the future; the competition pattern of bird flu vaccine is stable, and suspension culture is the breakthrough in the future; there are many enterprises producing classical swine fever and porcine blue ear vaccine, and the competition is fierce. It is expected to take the lead to withdraw from the scope of strong immunity, and the porcine blue ear genetic engineering vaccine is expected to break through. Porcine circus vaccine is the largest conventional vaccine with low market penetration, which is mainly dominated by foreign-funded enterprises and has great substitution opportunities for domestic enterprises.